{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:40:05Z","timestamp":1748857205734,"version":"3.41.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijgc.2025.101824","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:56:57Z","timestamp":1744354617000},"page":"101824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extending the timing for secondary cytoreductive surgery after second-line chemotherapy in relapsed ovarian cancer: the EXTENSION study"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-4562","authenticated-orcid":false,"given":"Carmine","family":"Conte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Congedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Romana","family":"Scanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Parise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Ghirardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-9041","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.ijgc.2025.101824_bib1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.ijgc.2025.101824_bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101824_bib3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101824_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101824_bib5","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/s41591-024-02981-0","article-title":"Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ijgc.2025.101824_bib6","unstructured":"Ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024. NCCN guidelines. National Comprehensive Cancer Network. Accessed October 14, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453."},{"issue":"3","key":"10.1016\/j.ijgc.2025.101824_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101824_bib8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2025.101824_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101824_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","article-title":"Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors","volume":"131","author":"Petrillo","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101824_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/ijgc-2022-003904","article-title":"Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer","volume":"33","author":"Conte","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101824_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline, version 1.1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101824_bib13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2025.101824_bib14","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-18-3335","article-title":"Early modeled longitudinal CA-125 kinetics and survival of ovarian cancer patients: a GINECO AGO MRC CTU study","volume":"25","author":"Colomban","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101824_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-022-01732-7","article-title":"Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era","volume":"127","author":"You","year":"2022","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.ijgc.2025.101824_bib16","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101824_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2013.05.013","article-title":"The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from Calypso trial (a GINECO-GCIG study)","volume":"130","author":"You","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101824_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104477","article-title":"Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10","volume":"89","author":"Colomban","year":"2023","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101824_bib19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2217\/bmm-2022-0923","article-title":"KELIM score predicts outcome in patients with platinum-resistant\/refractory recurrent ovarian cancer","volume":"17","author":"Kus","year":"2023","journal-title":"Biomark Med"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101824_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","article-title":"Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial","volume":"36","author":"Harter","year":"2025","journal-title":"Ann Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:14:37Z","timestamp":1748855677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25009430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1048891X25009430"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101824","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extending the timing for secondary cytoreductive surgery after second-line chemotherapy in relapsed ovarian cancer: the EXTENSION study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101824"}}